Overview
Efficacy and Safety of Rizatriptan-Naproxen (10/550 mg) in the Acute Treatment of Migraine
Status:
Not yet recruiting
Not yet recruiting
Trial end date:
2022-10-30
2022-10-30
Target enrollment:
0
0
Participant gender:
All
All
Summary
A phase III study, multicenter, double-blind, double-dummy, randomized, single-dose, placebo-controlled study to evaluate the efficacy and safety of Rizatriptan-Naproxen (10/550 mg) in the acute treatment of migraine.Phase:
Phase 3Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Eurofarma Laboratorios S.A.Treatments:
Naproxen
Rizatriptan
Criteria
Inclusion Criteria:- Patients of both sexes;
- Aged between 18 and 65 years old;
- Capable and willing to give free and informed informed consent in writing;
- Migraine patients with or without aura, according to the International Headache
Society (IHS).
Exclusion Criteria:
- Chronic migraine;
- Headache other than migraine (that is, tension-type headache, sinusitis, etc.).